Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by funky99on May 06, 2015 1:53pm

46 Views

Post# 23700611

RE:RE:RE:RE:Over sold?

1st day in a while we see only green buying agree and not the usual brokers messing in the background. Might be some investor that attended the Bloom Burton Conference. TD is on the buying side today.

Long here I will sit on my share for a while. GLTA.

Recent Trades - Last 10 of 29

Time ET	Ex	Price	Change	Volume	Buyer	Seller	Markers
13:23:49	V	0.235	0.015	3,500	99 Jitney	2 RBC
13:23:28	V	0.23	0.01	400	62 Haywood	79 CIBC
13:23:28	V	0.23	0.01	3,500	7 TD Sec	79 CIBC
13:22:40	V	0.23	0.01	10,000	7 TD Sec	79 CIBC
13:16:03	V	0.23	0.01	11,500	7 TD Sec	79 CIBC
13:16:03	V	0.23	0.01	10,000	7 TD Sec	2 RBC
13:16:03	V	0.23	0.01	18,000	7 TD Sec	19 Desjardins
13:16:03	V	0.22		500	7 TD Sec	79 CIBC
13:02:25	V	0.22		1,500	99 Jitney	79 CIBC
12:47:07	V	0.23	0.01	11,000	7 TD Sec	19 Desjardins